nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A5—Crohn's disease	0.892	1	CbGaD
Amphetamine—SLC22A3—Organic cation transport—SLC22A5—Crohn's disease	0.00608	0.075	CbGpPWpGaD
Amphetamine—SLC22A3—Organic cation transport—SLC22A4—Crohn's disease	0.00608	0.075	CbGpPWpGaD
Amphetamine—SLC22A5—Organic cation transport—SLC22A4—Crohn's disease	0.00606	0.0748	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—CREM—Crohn's disease	0.00488	0.0602	CbGpPWpGaD
Amphetamine—SLC22A3—Organic cation/anion/zwitterion transport—SLC22A4—Crohn's disease	0.00412	0.0509	CbGpPWpGaD
Amphetamine—SLC22A3—Organic cation/anion/zwitterion transport—SLC22A5—Crohn's disease	0.00412	0.0509	CbGpPWpGaD
Amphetamine—SLC22A5—Organic cation/anion/zwitterion transport—SLC22A4—Crohn's disease	0.00411	0.0507	CbGpPWpGaD
Amphetamine—SLC6A3—Parkinsons Disease Pathway—LRRK2—Crohn's disease	0.00117	0.0145	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.00104	0.0129	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.000987	0.0122	CbGpPWpGaD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A4—Crohn's disease	0.000955	0.0118	CbGpPWpGaD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—Crohn's disease	0.000955	0.0118	CbGpPWpGaD
Amphetamine—TAAR1—G alpha (s) signalling events—PTGER4—Crohn's disease	0.000837	0.0103	CbGpPWpGaD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—Crohn's disease	0.000826	0.0102	CbGpPWpGaD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A4—Crohn's disease	0.000826	0.0102	CbGpPWpGaD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A4—Crohn's disease	0.000823	0.0102	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—ACKR2—Crohn's disease	0.000793	0.00979	CbGpPWpGaD
Amphetamine—SLC6A4—Serotonin Transporter Activity—IL1B—Crohn's disease	0.000778	0.0096	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—MLN—Crohn's disease	0.000752	0.00928	CbGpPWpGaD
Amphetamine—Dysmenorrhoea—Mesalazine—Crohn's disease	0.000746	0.0283	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.000684	0.00844	CbGpPWpGaD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A4—Crohn's disease	0.000643	0.00793	CbGpPWpGaD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—Crohn's disease	0.000643	0.00793	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.000636	0.00785	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CREM—Crohn's disease	0.000601	0.00741	CbGpPWpGaD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—Crohn's disease	0.000595	0.00734	CbGpPWpGaD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—Crohn's disease	0.000569	0.00702	CbGpPWpGaD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A4—Crohn's disease	0.000569	0.00702	CbGpPWpGaD
Amphetamine—Libido decreased—Mesalazine—Crohn's disease	0.000531	0.0202	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CCR9—Crohn's disease	0.000521	0.00643	CbGpPWpGaD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—Crohn's disease	0.000514	0.00635	CbGpPWpGaD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—Crohn's disease	0.000513	0.00633	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—CREM—Crohn's disease	0.000491	0.00605	CbGpPWpGaD
Amphetamine—Disturbance in sexual arousal—Mesalazine—Crohn's disease	0.000489	0.0185	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.000487	0.0185	CcSEcCtD
Amphetamine—Affect lability—Mesalazine—Crohn's disease	0.000485	0.0184	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—GPR65—Crohn's disease	0.000485	0.00598	CbGpPWpGaD
Amphetamine—Mood swings—Mesalazine—Crohn's disease	0.000466	0.0177	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000453	0.00559	CbGpPWpGaD
Amphetamine—Abdominal pain upper—Mesalazine—Crohn's disease	0.00045	0.0171	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—IL6—Crohn's disease	0.000443	0.00547	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000434	0.00535	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000434	0.00535	CbGpPWpGaD
Amphetamine—Anorexia—Mercaptopurine—Crohn's disease	0.000425	0.0161	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—MLN—Crohn's disease	0.000425	0.00524	CbGpPWpGaD
Amphetamine—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.000413	0.0157	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—ACKR2—Crohn's disease	0.000407	0.00502	CbGpPWpGaD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—Crohn's disease	0.0004	0.00494	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000399	0.00492	CbGpPWpGaD
Amphetamine—Viral infection—Prednisone—Crohn's disease	0.000397	0.0151	CcSEcCtD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—Crohn's disease	0.000394	0.00487	CbGpPWpGaD
Amphetamine—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000388	0.0147	CcSEcCtD
Amphetamine—Decreased appetite—Mercaptopurine—Crohn's disease	0.000388	0.0147	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—MLN—Crohn's disease	0.000386	0.00476	CbGpPWpGaD
Amphetamine—Weight decreased—Mesalazine—Crohn's disease	0.000385	0.0146	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000385	0.0146	CcSEcCtD
Amphetamine—Depression—Mesalazine—Crohn's disease	0.000378	0.0144	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.000376	0.0143	CcSEcCtD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000375	0.00463	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000375	0.00463	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000374	0.00461	CbGpPWpGaD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—Crohn's disease	0.000374	0.00461	CbGpPWpGaD
Amphetamine—Urinary tract infection—Mesalazine—Crohn's disease	0.000369	0.014	CcSEcCtD
Amphetamine—Sweating—Mesalazine—Crohn's disease	0.000364	0.0138	CcSEcCtD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—Crohn's disease	0.000355	0.00437	CbGpPWpGaD
Amphetamine—Erythema multiforme—Azathioprine—Crohn's disease	0.000354	0.0134	CcSEcCtD
Amphetamine—Body temperature increased—Mercaptopurine—Crohn's disease	0.000353	0.0134	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CCR6—Crohn's disease	0.000345	0.00426	CbGpPWpGaD
Amphetamine—SLC6A4—Monoamine Transport—IL1B—Crohn's disease	0.000331	0.00409	CbGpPWpGaD
Amphetamine—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000329	0.0125	CcSEcCtD
Amphetamine—Erythema multiforme—Mesalazine—Crohn's disease	0.000322	0.0122	CcSEcCtD
Amphetamine—Euphoric mood—Prednisone—Crohn's disease	0.000308	0.0117	CcSEcCtD
Amphetamine—Methamphetamine—SLC22A5—Crohn's disease	0.000308	0.456	CrCbGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000306	0.00377	CbGpPWpGaD
Amphetamine—Diarrhoea—Mercaptopurine—Crohn's disease	0.000305	0.0116	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—PTGER4—Crohn's disease	0.000304	0.00375	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—CREM—Crohn's disease	0.0003	0.0037	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CCR9—Crohn's disease	0.000295	0.00363	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000292	0.0036	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000292	0.0036	CbGpPWpGaD
Amphetamine—Tension—Mesalazine—Crohn's disease	0.000291	0.011	CcSEcCtD
Amphetamine—Nervousness—Mesalazine—Crohn's disease	0.000288	0.0109	CcSEcCtD
Amphetamine—SLC6A2—Monoamine Transport—IL1B—Crohn's disease	0.000285	0.00351	CbGpPWpGaD
Amphetamine—Vomiting—Mercaptopurine—Crohn's disease	0.000284	0.0108	CcSEcCtD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—ACKR2—Crohn's disease	0.000284	0.0035	CbGpPWpGaD
Amphetamine—Injury—Prednisone—Crohn's disease	0.000283	0.0108	CcSEcCtD
Amphetamine—Rash—Mercaptopurine—Crohn's disease	0.000281	0.0107	CcSEcCtD
Amphetamine—Dermatitis—Mercaptopurine—Crohn's disease	0.000281	0.0107	CcSEcCtD
Amphetamine—Tremor—Mesalazine—Crohn's disease	0.000278	0.0105	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—GPR65—Crohn's disease	0.000274	0.00338	CbGpPWpGaD
Amphetamine—Angioedema—Mesalazine—Crohn's disease	0.000271	0.0103	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.00027	0.00333	CbGpPWpGaD
Amphetamine—Pseudoephedrine—TNF—Crohn's disease	0.000268	0.397	CrCbGaD
Amphetamine—TAAR1—Signaling by GPCR—CCR9—Crohn's disease	0.000267	0.0033	CbGpPWpGaD
Amphetamine—Nausea—Mercaptopurine—Crohn's disease	0.000265	0.0101	CcSEcCtD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000264	0.00326	CbGpPWpGaD
Amphetamine—Infection—Azathioprine—Crohn's disease	0.000264	0.01	CcSEcCtD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000264	0.00325	CbGpPWpGaD
Amphetamine—Palpitations—Mesalazine—Crohn's disease	0.000262	0.00995	CcSEcCtD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000259	0.00319	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000259	0.00319	CbGpPWpGaD
Amphetamine—Affect lability—Prednisone—Crohn's disease	0.000256	0.00974	CcSEcCtD
Amphetamine—Hypertension—Mesalazine—Crohn's disease	0.000256	0.00972	CcSEcCtD
Amphetamine—Psychotic disorder—Prednisone—Crohn's disease	0.000254	0.00966	CcSEcCtD
Amphetamine—Chest pain—Mesalazine—Crohn's disease	0.000252	0.00959	CcSEcCtD
Amphetamine—SLC6A3—Monoamine Transport—IL1B—Crohn's disease	0.000252	0.00311	CbGpPWpGaD
Amphetamine—Anxiety—Mesalazine—Crohn's disease	0.000252	0.00955	CcSEcCtD
Amphetamine—Irritability—Prednisone—Crohn's disease	0.000249	0.00944	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—GPR65—Crohn's disease	0.000249	0.00307	CbGpPWpGaD
Amphetamine—Dry mouth—Mesalazine—Crohn's disease	0.000247	0.00937	CcSEcCtD
Amphetamine—Mood swings—Prednisone—Crohn's disease	0.000247	0.00937	CcSEcCtD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.000243	0.003	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Mesalazine—Crohn's disease	0.000242	0.00919	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—ACKR2—Crohn's disease	0.00024	0.00297	CbGpPWpGaD
Amphetamine—Infection—Mesalazine—Crohn's disease	0.00024	0.00913	CcSEcCtD
Amphetamine—SLC6A4—Monoamine Transport—TNF—Crohn's disease	0.00024	0.00297	CbGpPWpGaD
Amphetamine—Tachycardia—Mesalazine—Crohn's disease	0.000236	0.00897	CcSEcCtD
Amphetamine—Hyperhidrosis—Mesalazine—Crohn's disease	0.000234	0.00888	CcSEcCtD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.000234	0.00288	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.000233	0.00287	CbGpPWpGaD
Amphetamine—Anorexia—Mesalazine—Crohn's disease	0.000231	0.00876	CcSEcCtD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.00023	0.00284	CbGpPWpGaD
Amphetamine—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000229	0.00871	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—MLN—Crohn's disease	0.000228	0.00281	CbGpPWpGaD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—Crohn's disease	0.000223	0.00275	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000221	0.00272	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000221	0.00272	CbGpPWpGaD
Amphetamine—Insomnia—Mesalazine—Crohn's disease	0.000219	0.00831	CcSEcCtD
Amphetamine—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000217	0.00825	CcSEcCtD
Amphetamine—Dyspnoea—Mesalazine—Crohn's disease	0.000216	0.00819	CcSEcCtD
Amphetamine—Somnolence—Mesalazine—Crohn's disease	0.000215	0.00817	CcSEcCtD
Amphetamine—Dyspepsia—Mesalazine—Crohn's disease	0.000213	0.00809	CcSEcCtD
Amphetamine—Decreased appetite—Mesalazine—Crohn's disease	0.00021	0.00799	CcSEcCtD
Amphetamine—Abdominal pain—Azathioprine—Crohn's disease	0.00021	0.00797	CcSEcCtD
Amphetamine—Body temperature increased—Azathioprine—Crohn's disease	0.00021	0.00797	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000209	0.00793	CcSEcCtD
Amphetamine—Fatigue—Mesalazine—Crohn's disease	0.000209	0.00792	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—TAGAP—Crohn's disease	0.000208	0.00257	CbGpPWpGaD
Amphetamine—Erectile dysfunction—Prednisone—Crohn's disease	0.000207	0.00787	CcSEcCtD
Amphetamine—Constipation—Mesalazine—Crohn's disease	0.000207	0.00786	CcSEcCtD
Amphetamine—SLC6A2—Monoamine Transport—TNF—Crohn's disease	0.000207	0.00255	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000206	0.00254	CbGpPWpGaD
Amphetamine—Weight decreased—Prednisone—Crohn's disease	0.000204	0.00773	CcSEcCtD
Amphetamine—DRD2—G alpha (i) signalling events—CCR9—Crohn's disease	0.000201	0.00248	CbGpPWpGaD
Amphetamine—Depression—Prednisone—Crohn's disease	0.0002	0.0076	CcSEcCtD
Amphetamine—Acute coronary syndrome—Prednisone—Crohn's disease	0.000198	0.00751	CcSEcCtD
Amphetamine—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000198	0.00751	CcSEcCtD
Amphetamine—Myocardial infarction—Prednisone—Crohn's disease	0.000197	0.00747	CcSEcCtD
Amphetamine—Hypersensitivity—Azathioprine—Crohn's disease	0.000196	0.00743	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—CCR6—Crohn's disease	0.000195	0.00241	CbGpPWpGaD
Amphetamine—Urticaria—Mesalazine—Crohn's disease	0.000192	0.0073	CcSEcCtD
Amphetamine—Body temperature increased—Mesalazine—Crohn's disease	0.000191	0.00726	CcSEcCtD
Amphetamine—Abdominal pain—Mesalazine—Crohn's disease	0.000191	0.00726	CcSEcCtD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000191	0.00235	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000191	0.00235	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.00019	0.00235	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.000186	0.0023	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—ACKR2—Crohn's disease	0.000185	0.00228	CbGpPWpGaD
Amphetamine—SLC6A3—Monoamine Transport—TNF—Crohn's disease	0.000183	0.00226	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000182	0.00225	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RSPO3—Crohn's disease	0.000182	0.00225	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.000182	0.00224	CbGpPWpGaD
Amphetamine—Diarrhoea—Azathioprine—Crohn's disease	0.000182	0.0069	CcSEcCtD
Amphetamine—Hypersensitivity—Mesalazine—Crohn's disease	0.000178	0.00677	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL10—Crohn's disease	0.000178	0.00219	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CCR6—Crohn's disease	0.000177	0.00219	CbGpPWpGaD
Amphetamine—Dizziness—Azathioprine—Crohn's disease	0.000176	0.00667	CcSEcCtD
Amphetamine—DRD2—GPCR ligand binding—MLN—Crohn's disease	0.000175	0.00216	CbGpPWpGaD
Amphetamine—Asthenia—Mesalazine—Crohn's disease	0.000174	0.00659	CcSEcCtD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.000173	0.00214	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SEL1L—Crohn's disease	0.000173	0.00213	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—PTGER4—Crohn's disease	0.000172	0.00212	CbGpPWpGaD
Amphetamine—Vomiting—Azathioprine—Crohn's disease	0.000169	0.00641	CcSEcCtD
Amphetamine—Rash—Azathioprine—Crohn's disease	0.000168	0.00636	CcSEcCtD
Amphetamine—Dermatitis—Azathioprine—Crohn's disease	0.000167	0.00635	CcSEcCtD
Amphetamine—Headache—Azathioprine—Crohn's disease	0.000166	0.00632	CcSEcCtD
Amphetamine—Diarrhoea—Mesalazine—Crohn's disease	0.000166	0.00629	CcSEcCtD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.000161	0.00199	CbGpPWpGaD
Amphetamine—Dizziness—Mesalazine—Crohn's disease	0.00016	0.00608	CcSEcCtD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00016	0.00197	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCR9—Crohn's disease	0.000158	0.00195	CbGpPWpGaD
Amphetamine—Nausea—Azathioprine—Crohn's disease	0.000158	0.00599	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—PTGER4—Crohn's disease	0.000156	0.00192	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000155	0.00192	CbGpPWpGaD
Amphetamine—Vomiting—Mesalazine—Crohn's disease	0.000154	0.00584	CcSEcCtD
Amphetamine—Rash—Mesalazine—Crohn's disease	0.000153	0.00579	CcSEcCtD
Amphetamine—Dermatitis—Mesalazine—Crohn's disease	0.000152	0.00579	CcSEcCtD
Amphetamine—Headache—Mesalazine—Crohn's disease	0.000152	0.00576	CcSEcCtD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000148	0.00183	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000148	0.00183	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.000148	0.00183	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—GPR65—Crohn's disease	0.000147	0.00181	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—IL3—Crohn's disease	0.000146	0.00181	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000146	0.0018	CbGpPWpGaD
Amphetamine—Agitation—Prednisone—Crohn's disease	0.000144	0.00547	CcSEcCtD
Amphetamine—Nausea—Mesalazine—Crohn's disease	0.000144	0.00546	CcSEcCtD
Amphetamine—Angioedema—Prednisone—Crohn's disease	0.000143	0.00544	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000142	0.00175	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000137	0.00169	CbGpPWpGaD
Amphetamine—Convulsion—Prednisone—Crohn's disease	0.000136	0.00516	CcSEcCtD
Amphetamine—Hypertension—Prednisone—Crohn's disease	0.000135	0.00514	CcSEcCtD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000134	0.00166	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000134	0.00165	CbGpPWpGaD
Amphetamine—Anxiety—Prednisone—Crohn's disease	0.000133	0.00505	CcSEcCtD
Amphetamine—DRD2—G alpha (i) signalling events—CCR6—Crohn's disease	0.000133	0.00164	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL3—Crohn's disease	0.000133	0.00164	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000131	0.00162	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000131	0.00162	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—RASGRP1—Crohn's disease	0.000128	0.00159	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Prednisone—Crohn's disease	0.000128	0.00486	CcSEcCtD
Amphetamine—Infection—Prednisone—Crohn's disease	0.000127	0.00483	CcSEcCtD
Amphetamine—Tachycardia—Prednisone—Crohn's disease	0.000125	0.00475	CcSEcCtD
Amphetamine—MAOB—Metabolism—PLA2G4F—Crohn's disease	0.000124	0.00153	CbGpPWpGaD
Amphetamine—Hyperhidrosis—Prednisone—Crohn's disease	0.000124	0.0047	CcSEcCtD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.000123	0.00152	CbGpPWpGaD
Amphetamine—Anorexia—Prednisone—Crohn's disease	0.000122	0.00463	CcSEcCtD
Amphetamine—DRD2—GPCR ligand binding—CCR9—Crohn's disease	0.000122	0.0015	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GPX4—Crohn's disease	0.000121	0.0015	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000119	0.00147	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000118	0.00146	CbGpPWpGaD
Amphetamine—Insomnia—Prednisone—Crohn's disease	0.000116	0.0044	CcSEcCtD
Amphetamine—DRD2—GPCR ligand binding—GPR65—Crohn's disease	0.000113	0.00139	CbGpPWpGaD
Amphetamine—Dyspepsia—Prednisone—Crohn's disease	0.000113	0.00428	CcSEcCtD
Amphetamine—Decreased appetite—Prednisone—Crohn's disease	0.000111	0.00423	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CXCL8—Crohn's disease	0.000111	0.00137	CbGpPWpGaD
Amphetamine—Fatigue—Prednisone—Crohn's disease	0.00011	0.00419	CcSEcCtD
Amphetamine—Constipation—Prednisone—Crohn's disease	0.000109	0.00416	CcSEcCtD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.000109	0.00134	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000106	0.0013	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—MTMR3—Crohn's disease	0.000106	0.0013	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PLA2G4F—Crohn's disease	0.000105	0.0013	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Prednisone—Crohn's disease	0.000105	0.00398	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—CCR6—Crohn's disease	0.000105	0.00129	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000105	0.00129	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—IL2RA—Crohn's disease	0.000102	0.00126	CbGpPWpGaD
Amphetamine—Urticaria—Prednisone—Crohn's disease	0.000102	0.00386	CcSEcCtD
Amphetamine—Abdominal pain—Prednisone—Crohn's disease	0.000101	0.00384	CcSEcCtD
Amphetamine—Body temperature increased—Prednisone—Crohn's disease	0.000101	0.00384	CcSEcCtD
Amphetamine—Nateglinide—ALB—Crohn's disease	9.91e-05	0.147	CrCbGaD
Amphetamine—DRD2—GPCR downstream signaling—MLN—Crohn's disease	9.91e-05	0.00122	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—Crohn's disease	9.73e-05	0.0012	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	9.72e-05	0.0012	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ACKR2—Crohn's disease	9.49e-05	0.00117	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RBX1—Crohn's disease	9.46e-05	0.00117	CbGpPWpGaD
Amphetamine—Hypersensitivity—Prednisone—Crohn's disease	9.43e-05	0.00358	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL1B—Crohn's disease	9.33e-05	0.00115	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	9.31e-05	0.00115	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL2RA—Crohn's disease	9.31e-05	0.00115	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—GCKR—Crohn's disease	9.26e-05	0.00114	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	9.24e-05	0.00114	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTGER4—Crohn's disease	9.21e-05	0.00114	CbGpPWpGaD
Amphetamine—Asthenia—Prednisone—Crohn's disease	9.19e-05	0.00349	CcSEcCtD
Amphetamine—DRD2—Signaling by GPCR—MLN—Crohn's disease	9e-05	0.00111	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MTMR3—Crohn's disease	8.93e-05	0.0011	CbGpPWpGaD
Amphetamine—Diarrhoea—Prednisone—Crohn's disease	8.76e-05	0.00333	CcSEcCtD
Amphetamine—Dizziness—Prednisone—Crohn's disease	8.47e-05	0.00322	CcSEcCtD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—ALB—Crohn's disease	8.41e-05	0.00104	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—ALB—Crohn's disease	8.39e-05	0.00103	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—UBE2D1—Crohn's disease	8.3e-05	0.00102	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—FADS1—Crohn's disease	8.22e-05	0.00101	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	8.19e-05	0.00101	CbGpPWpGaD
Amphetamine—Vomiting—Prednisone—Crohn's disease	8.14e-05	0.00309	CcSEcCtD
Amphetamine—Rash—Prednisone—Crohn's disease	8.07e-05	0.00307	CcSEcCtD
Amphetamine—Dermatitis—Prednisone—Crohn's disease	8.07e-05	0.00306	CcSEcCtD
Amphetamine—DRD2—GPCR ligand binding—CCR6—Crohn's disease	8.05e-05	0.000993	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RIPK2—Crohn's disease	8.05e-05	0.000993	CbGpPWpGaD
Amphetamine—Headache—Prednisone—Crohn's disease	8.02e-05	0.00305	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—IL3—Crohn's disease	7.85e-05	0.000968	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GPX4—Crohn's disease	7.7e-05	0.00095	CbGpPWpGaD
Amphetamine—Nausea—Prednisone—Crohn's disease	7.61e-05	0.00289	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—RASGRP1—Crohn's disease	7.59e-05	0.000937	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GCKR—Crohn's disease	7.44e-05	0.000918	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—PTGER4—Crohn's disease	7.09e-05	0.000875	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—FADS1—Crohn's disease	6.96e-05	0.000859	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—JAK2—Crohn's disease	6.89e-05	0.00085	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SOCS1—Crohn's disease	6.88e-05	0.000848	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CCR9—Crohn's disease	6.87e-05	0.000847	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—Crohn's disease	6.77e-05	0.000835	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—TYK2—Crohn's disease	6.56e-05	0.000809	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—Crohn's disease	6.55e-05	0.000808	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GPX4—Crohn's disease	6.52e-05	0.000804	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GPR65—Crohn's disease	6.39e-05	0.000788	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GCKR—Crohn's disease	6.29e-05	0.000776	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CXCL8—Crohn's disease	6.29e-05	0.000776	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—JAK2—Crohn's disease	6.26e-05	0.000772	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCR9—Crohn's disease	6.24e-05	0.00077	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PLA2G4F—Crohn's disease	6.05e-05	0.000746	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SMAD3—Crohn's disease	5.94e-05	0.000733	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—Crohn's disease	5.8e-05	0.000716	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GPR65—Crohn's disease	5.8e-05	0.000715	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CXCL8—Crohn's disease	5.71e-05	0.000704	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ACKR2—Crohn's disease	5.61e-05	0.000692	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL2RA—Crohn's disease	5.5e-05	0.000678	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—Crohn's disease	5.46e-05	0.000674	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MLN—Crohn's disease	5.32e-05	0.000656	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MTMR3—Crohn's disease	5.14e-05	0.000634	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—ALB—Crohn's disease	4.94e-05	0.00061	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TAGAP—Crohn's disease	4.86e-05	0.0006	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CCR6—Crohn's disease	4.55e-05	0.000561	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—IL6—Crohn's disease	4.46e-05	0.00055	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCL8—Crohn's disease	4.29e-05	0.000529	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—ALB—Crohn's disease	4.28e-05	0.000528	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—ALB—Crohn's disease	4.26e-05	0.000526	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RSPO3—Crohn's disease	4.25e-05	0.000524	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCR6—Crohn's disease	4.13e-05	0.00051	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SEL1L—Crohn's disease	4.03e-05	0.000497	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—FADS1—Crohn's disease	4.01e-05	0.000494	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PTGER4—Crohn's disease	4.01e-05	0.000494	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TYK2—Crohn's disease	3.87e-05	0.000478	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GPX4—Crohn's disease	3.75e-05	0.000463	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—JAK2—Crohn's disease	3.7e-05	0.000456	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCR9—Crohn's disease	3.68e-05	0.000455	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PTGER4—Crohn's disease	3.64e-05	0.000449	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GCKR—Crohn's disease	3.62e-05	0.000447	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GPR65—Crohn's disease	3.43e-05	0.000423	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL3—Crohn's disease	3.41e-05	0.000421	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	3.41e-05	0.00042	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLA2G4F—Crohn's disease	3.39e-05	0.000418	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL8—Crohn's disease	3.37e-05	0.000416	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—Crohn's disease	3.33e-05	0.000411	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—RASGRP1—Crohn's disease	3.3e-05	0.000407	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6—Crohn's disease	3.21e-05	0.000396	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL3—Crohn's disease	3.1e-05	0.000382	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—RASGRP1—Crohn's disease	3e-05	0.00037	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—Crohn's disease	2.95e-05	0.000364	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTMR3—Crohn's disease	2.88e-05	0.000356	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—Crohn's disease	2.73e-05	0.000337	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STAT3—Crohn's disease	2.71e-05	0.000335	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL8—Crohn's disease	2.59e-05	0.00032	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCR6—Crohn's disease	2.44e-05	0.000301	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL2RA—Crohn's disease	2.39e-05	0.000295	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ALB—Crohn's disease	2.37e-05	0.000292	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—FADS1—Crohn's disease	2.25e-05	0.000277	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RBX1—Crohn's disease	2.21e-05	0.000272	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL2RA—Crohn's disease	2.17e-05	0.000268	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTGER4—Crohn's disease	2.15e-05	0.000265	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GPX4—Crohn's disease	2.1e-05	0.00026	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—Crohn's disease	2.07e-05	0.000256	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GCKR—Crohn's disease	2.03e-05	0.000251	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ALB—Crohn's disease	2e-05	0.000247	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—UBE2D1—Crohn's disease	1.94e-05	0.000239	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—Crohn's disease	1.89e-05	0.000234	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RIPK2—Crohn's disease	1.88e-05	0.000232	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL3—Crohn's disease	1.83e-05	0.000226	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RASGRP1—Crohn's disease	1.77e-05	0.000218	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—Crohn's disease	1.75e-05	0.000216	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—JAK2—Crohn's disease	1.61e-05	0.000198	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SOCS1—Crohn's disease	1.6e-05	0.000198	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—TYK2—Crohn's disease	1.53e-05	0.000189	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL8—Crohn's disease	1.47e-05	0.000181	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—JAK2—Crohn's disease	1.46e-05	0.00018	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SMAD3—Crohn's disease	1.38e-05	0.000171	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL8—Crohn's disease	1.33e-05	0.000164	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL2RA—Crohn's disease	1.28e-05	0.000158	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALB—Crohn's disease	1.15e-05	0.000142	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—Crohn's disease	1.01e-05	0.000124	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TYK2—Crohn's disease	9.03e-06	0.000111	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—JAK2—Crohn's disease	8.62e-06	0.000106	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL8—Crohn's disease	7.87e-06	9.7e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—Crohn's disease	7.48e-06	9.23e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALB—Crohn's disease	6.47e-06	7.98e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT3—Crohn's disease	6.33e-06	7.8e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—Crohn's disease	5.66e-06	6.98e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—Crohn's disease	4.42e-06	5.45e-05	CbGpPWpGaD
